Generated by rs-summarizer Version unbekannt
Persona Adopted: Senior Research Director in Stem Cell Biology and Computational Genomics
Abstract
This compendium of research details the construction and validation of the Human Endoderm-derived Organoid Cell Atlas (HEOCA), an integrated transcriptomic framework comprising nearly one million single-cell profiles across nine tissue types. By harmonizing data from 218 samples and 55 publications, the HEOCA establishes a high-fidelity reference for assessing organoid maturation and "on-target" cellular composition against primary fetal and adult tissues. Building upon this atlas, the research introduces two advanced bioengineered platforms: Intestinal Immuno-Organoids (IIOs) and "Mini-Colons."
The IIO model incorporates autologous tissue-resident memory T (TRM) cells into epithelial structures, enabling the study of interlineage immune interactions and drug-induced inflammation, specifically regarding T-cell-bispecific (TCB) antibody toxicities. Simultaneously, the "Mini-Colon" platform utilizes hydrogel scaffolds and asymmetric growth factor stimulation to achieve in vivo-like cellular patterning, homeostatic cell turnover, and mature colonocyte differentiation. Collectively, these studies demonstrate that integrating large-scale transcriptomic references with bioengineered niche environments significantly improves the predictive power of in vitro models for drug safety, disease modeling, and regenerative medicine.
Key Takeaways and Technical Synthesis
-
[HEOCA Integration] Large-Scale Transcriptomic Mapping:
- Integrated approximately 1,000,000 cells from 218 experiments covering lung, liver, biliary system, stomach, pancreas, prostate, salivary glands, and small/large intestines.
- Utilized scPoli for data-aware integration to mitigate batch effects across 12 different sequencing protocols (e.g., Smart-seq, 10x Genomics).
- Identified 48 distinct level-2 cell types, establishing consistent markers such as OLFM4 for stem cells and TP63 for basal cells across all protocols.
-
[Fidelity Assessment] Mapping Organoids to Primary Tissue:
- PSC-derived organoids predominantly exhibit fetal transcriptomic signatures, whereas ASC-derived models align more closely with adult primary tissue.
- Benchmarking revealed that pluripotent stem cell (PSC) models often produce "off-target" cells due to incomplete specification, requiring HEOCA-based "on-target" percentages to validate protocol accuracy.
-
[IIO Development] Autologous Immuno-Organoid Architecture:
- Successfully integrated tissue-resident memory T (TRM) cells (CD103+, CD69+) into epithelial organoids using an enzyme-free "crawl-out" isolation method.
- Observed "flossing" behavior in intraepithelial lymphocytes (IELs), where T cells integrate into basolateral junctions at a physiological ratio of 1:16 (immune to epithelial cells).
-
[Immune Toxicity] Recapitulating TCB-induced Inflammation:
- IIOs effectively modeled clinical toxicities of Solitomab (EpCAM-targeting TCB), showing rapid caspase 3/7 induction at concentrations as low as 40 pg/ml.
- Transcriptomic analysis identified a TH1-like CD4+ population as the primary driver of early inflammation, preceding the recruitment of cytotoxic CD8+ IELs.
- Identified the Rho pathway (via ROCK inhibition) and TNF-alpha as viable targets to mitigate immunotherapy-associated intestinal damage.
-
[Mini-Colon Bioengineering] Scaffold-Guided Morphogenesis:
- Integrated organ-on-a-chip technology with laser-ablated hydrogel scaffolds to replicate colonic crypt-villus architecture.
- Employed asymmetric growth factor stimulation (basal Wnt/NRG1 vs. apical differentiation media) to enable long-term (1 month+) homeostatic culture without passaging.
- Achieved functional zonation: FABP1+ colonocytes at the luminal surface and OLFM4+ stem cells restricted to crypt bases.
-
[Functional Maturity] Mucus Barrier and Nutrient Uptake:
- Mini-colons produced a thick, physiological mucus layer composed of MUC2 and MUC5B, visible via Alcian Blue/PAS staining.
- Demonstrated nutrient uptake capabilities using propargyl-choline click-chemistry, outperforming traditional Caco-2 models in metabolic fidelity (e.g., high CYP3A4 and CES2 expression).
-
[Preclinical Validation] Predicting Gastrointestinal Toxicity (GIT):
- Differential toxicological profiling of AML drugs: Cytarabine targeted S-phase proliferative cells in the crypt, while Idasanutlin (MDM2 inhibitor) triggered rapid, widespread p53-mediated apoptosis and epithelial shedding.
- The platform successfully predicted rapid-onset diarrhea (Idasanutlin) vs. delayed mucositis (Cytarabine), correlating with observed clinical patient outcomes.